Company Description
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Hung-Wen Chen |
Contact Details
Address: 989 East Hillsdale Blvd., Suite 220 Foster City, California 94404 United States | |
| Phone | 650 209 4055 |
| Website | apollomicsinc.com |
Stock Details
| Ticker Symbol | APLM |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001944885 |
| ISIN Number | KYG0411D1236 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hung-Wen Chen | Chief Executive Officer and Chairman of the Board |
| K. H. Lin C.A.I.A., M.B.A. | Chief Financial Officer |
| Yi-Kuei Chen | Director and Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2025 | 6-K | Report of foreign issuer |
| Nov 18, 2025 | 6-K | Report of foreign issuer |
| Oct 21, 2025 | 6-K | Report of foreign issuer |
| Oct 16, 2025 | 6-K | Report of foreign issuer |
| Oct 14, 2025 | 6-K | Report of foreign issuer |
| Sep 25, 2025 | 6-K | Report of foreign issuer |
| Sep 9, 2025 | SCHEDULE 13D | Filing |
| Sep 5, 2025 | SCHEDULE 13G/A | Filing |
| Sep 5, 2025 | 6-K | Report of foreign issuer |
| Sep 3, 2025 | 6-K | Report of foreign issuer |